[{"orgOrder":0,"company":"PANTHERx Rare Pharmacy","sponsor":"Blueprint Medicines","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Partnership","leadProduct":"Avapritinib","moa":"PDGFRA","graph1":"Oncology","graph2":"Approved","graph3":"PANTHERx Rare Pharmacy","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"PANTHERx Rare Pharmacy \/ Blueprint Medicines","highestDevelopmentStatusID":"12","companyTruncated":"PANTHERx Rare Pharmacy \/ Blueprint Medicines"},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Avapritinib","moa":"PDGFRA","graph1":"Oncology","graph2":"Approved","graph3":"Blueprint Medicines","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Blueprint Medicines \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Blueprint Medicines \/ Not Applicable"},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Avapritinib","moa":"PDGFRA","graph1":"Hematology","graph2":"Approved","graph3":"Blueprint Medicines","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Blueprint Medicines \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Blueprint Medicines \/ Not Applicable"},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Avapritinib","moa":"PDGFRA","graph1":"Oncology","graph2":"Approved","graph3":"Blueprint Medicines","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Blueprint Medicines \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Blueprint Medicines \/ Not Applicable"},{"orgOrder":0,"company":"CStone Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Avapritinib","moa":"PDGFRA","graph1":"Oncology","graph2":"Approved","graph3":"CStone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"CStone Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CStone Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"CStone Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Avapritinib","moa":"PDGFRA","graph1":"Oncology","graph2":"Approved","graph3":"CStone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"CStone Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CStone Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Avapritinib","moa":"PDGFRA","graph1":"Hematology","graph2":"Approved","graph3":"Blueprint Medicines","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Blueprint Medicines \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Blueprint Medicines \/ Not Applicable"},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Avapritinib","moa":"PDGFRA","graph1":"Oncology","graph2":"Approved","graph3":"Blueprint Medicines","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Blueprint Medicines \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Blueprint Medicines \/ Not Applicable"},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Avapritinib","moa":"PDGFRA","graph1":"Oncology","graph2":"Approved","graph3":"Blueprint Medicines","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Blueprint Medicines \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Blueprint Medicines \/ Not Applicable"},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Avapritinib","moa":"PDGFRA","graph1":"Oncology","graph2":"Approved","graph3":"Blueprint Medicines","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Blueprint Medicines \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Blueprint Medicines \/ Not Applicable"},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Avapritinib","moa":"PDGFRA","graph1":"Hematology","graph2":"Approved","graph3":"Blueprint Medicines","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Blueprint Medicines \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Blueprint Medicines \/ Not Applicable"},{"orgOrder":0,"company":"CStone Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Avapritinib","moa":"PDGFRA","graph1":"Oncology","graph2":"Approved","graph3":"CStone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"CStone Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CStone Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Avapritinib","moa":"PDGFRA","graph1":"Hematology","graph2":"Approved","graph3":"Blueprint Medicines","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Blueprint Medicines \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Blueprint Medicines \/ Not Applicable"},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Avapritinib","moa":"PDGFRA","graph1":"Hematology","graph2":"Approved","graph3":"Blueprint Medicines","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Blueprint Medicines \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Blueprint Medicines \/ Not Applicable"},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Avapritinib","moa":"PDGFRA","graph1":"Oncology","graph2":"Approved","graph3":"Blueprint Medicines","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Blueprint Medicines \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Blueprint Medicines \/ Not Applicable"},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Avapritinib","moa":"PDGFRA","graph1":"Oncology","graph2":"Approved","graph3":"Blueprint Medicines","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Blueprint Medicines \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Blueprint Medicines \/ Not Applicable"},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Blueprint Medicines","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Avapritinib","moa":"PDGFRA","graph1":"Oncology","graph2":"Approved","graph3":"Catalent Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Catalent Pharma Solutions \/ Blueprint Medicines","highestDevelopmentStatusID":"12","companyTruncated":"Catalent Pharma Solutions \/ Blueprint Medicines"},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Avapritinib","moa":"PDGFRA","graph1":"Hematology","graph2":"Approved","graph3":"Blueprint Medicines","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Blueprint Medicines \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Blueprint Medicines \/ Not Applicable"},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"Sixth Street","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Collaboration","leadProduct":"Avapritinib","moa":"PDGFRA","graph1":"Oncology","graph2":"Approved","graph3":"Blueprint Medicines","amount2":0.25,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0.25,"dosageForm":"Tablet","sponsorNew":"Blueprint Medicines \/ Sixth Street","highestDevelopmentStatusID":"12","companyTruncated":"Blueprint Medicines \/ Sixth Street"},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Avapritinib","moa":"PDGFRA","graph1":"Hematology","graph2":"Approved","graph3":"Blueprint Medicines","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Blueprint Medicines \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Blueprint Medicines \/ Not Applicable"},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Avapritinib","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"Blueprint Medicines","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Blueprint Medicines \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Blueprint Medicines \/ Not Applicable"},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Avapritinib","moa":"PDGFRA","graph1":"Oncology","graph2":"Approved","graph3":"Blueprint Medicines","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Blueprint Medicines \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Blueprint Medicines \/ Not Applicable"},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Avapritinib","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"Blueprint Medicines","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Blueprint Medicines \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Blueprint Medicines \/ Not Applicable"},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Avapritinib","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"Blueprint Medicines","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Blueprint Medicines \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Blueprint Medicines \/ Not Applicable"},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Avapritinib","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"Blueprint Medicines","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Blueprint Medicines \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Blueprint Medicines \/ Not Applicable"},{"orgOrder":0,"company":"CStone Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Avapritinib","moa":"","graph1":"Immunology","graph2":"Approved","graph3":"CStone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"CStone Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CStone Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Avapritinib","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"Blueprint Medicines","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Blueprint Medicines \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Blueprint Medicines \/ Not Applicable"},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Avapritinib","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"Blueprint Medicines","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Blueprint Medicines \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Blueprint Medicines \/ Not Applicable"},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Avapritinib","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"Blueprint Medicines","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Blueprint Medicines \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Blueprint Medicines \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals for Avapritinib

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          PharmaVenue
                          Not Confirmed
                          PharmaVenue
                          Not Confirmed

                          Details : Ayvakyt (avapritinib) is a kinase inhibitor, works by potently and selectively target KIT D816V. It is approved by european commission for the treatment of indolent systemic mastocytosis (ISM).

                          Brand Name : Ayvakyt

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          December 13, 2023

                          Lead Product(s) : Avapritinib

                          Therapeutic Area : Immunology

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          02

                          PharmaVenue
                          Not Confirmed
                          PharmaVenue
                          Not Confirmed

                          Details : AYVAKYT® (avapritinib) is a kinase inhibitor approved by the European Commission for the treatment of adult patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with an associated hematological neoplasm (SM-AHN) or mast cell leuke...

                          Brand Name : Ayvakit

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          November 10, 2023

                          Lead Product(s) : Avapritinib

                          Therapeutic Area : Immunology

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          03

                          PharmaVenue
                          Not Confirmed
                          PharmaVenue
                          Not Confirmed

                          Details : Ayvakit (avapritinib) is a FDA approved kinase inhibitor for treatment adults with Indolent Systemic Mastocytosis, ASM, SM-AHN and MCL, also for adults with GIST harboring a PDGFRA exon 18 mutation, including PDGFRA D842V mutations.

                          Brand Name : Ayvakit

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          May 22, 2023

                          Lead Product(s) : Avapritinib

                          Therapeutic Area : Immunology

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          04

                          PharmaVenue
                          Not Confirmed
                          PharmaVenue
                          Not Confirmed

                          Details : Ayvakit (avapritinib) is a kinase inhibitor approved by the FDA for the treatment of adults with Advanced SM, ASM, SM-AHN and MCL, and adults with unresectable or metastatic GIST harboring a PDGFRA exon 18 mutation, including PDGFRA D842V mutations.

                          Brand Name : Ayvakit

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          February 14, 2023

                          Lead Product(s) : Avapritinib

                          Therapeutic Area : Immunology

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          05

                          PharmaVenue
                          Not Confirmed
                          PharmaVenue
                          Not Confirmed

                          Details : Ayvakit (avapritinib) is a kinase inhibitor approved by the FDA for the treatment of adults with Advanced SM, ASM, SM-AHN and MCL, and adults with unresectable or metastatic GIST harboring a PDGFRA exon 18 mutation, including PDGFRA D842V mutations.

                          Brand Name : Ayvakit

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          February 03, 2023

                          Lead Product(s) : Avapritinib

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          06

                          PharmaVenue
                          Not Confirmed
                          PharmaVenue
                          Not Confirmed

                          Details : Ayvakit (avapritinib) is a kinase inhibitor approved by the FDA for the treatment of adults with Advanced SM, ASM, SM-AHN and MCL, and adults with unresectable or metastatic GIST harboring a PDGFRA exon 18 mutation, including PDGFRA D842V mutations.

                          Brand Name : Ayvakit

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          January 23, 2023

                          Lead Product(s) : Avapritinib

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          07

                          PharmaVenue
                          Not Confirmed
                          PharmaVenue
                          Not Confirmed

                          Details : Ayvakit (avapritinib) is a FDA approved kinase inhibitor for treatment adults with Advanced SM, ASM, SM-AHN and MCL, also for adults with GIST harboring a PDGFRA exon 18 mutation, including PDGFRA D842V mutations.

                          Brand Name : Ayakit

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          December 11, 2022

                          Lead Product(s) : Avapritinib

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          08

                          PharmaVenue
                          Not Confirmed
                          PharmaVenue
                          Not Confirmed

                          Details : AYVAKIT (avapritinib) is a kinase inhibitor approved by the FDA for the treatment of adults with Advanced SM, including aggressive SM (ASM), SM with an associated hematological neoplasm (SM-AHN) and mast cell leukemia (MCL).

                          Brand Name : Ayvakit

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          November 22, 2022

                          Lead Product(s) : Avapritinib

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          09

                          PharmaVenue
                          Not Confirmed
                          PharmaVenue
                          Not Confirmed

                          Details : Key highlights include oral PATHFINDER trial, which reinforces transformative impact of AYVAKIT (avapritinib) as first-line treatment in advanced SM, and also highlights survival benefits after nearly four years of patient follow-up in advanced SM.

                          Brand Name : Ayvakit

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          November 03, 2022

                          Lead Product(s) : Avapritinib

                          Therapeutic Area : Immunology

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          10

                          PharmaVenue
                          Not Confirmed
                          PharmaVenue
                          Not Confirmed

                          Details : The trial, which was designed to assess AYVAKIT (avapritinib) plus best available care versus placebo plus best available care (control arm), achieved its primary endpoint with a highly significant difference in the mean change in total symptom score at ...

                          Brand Name : Ayvakit

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          August 17, 2022

                          Lead Product(s) : Avapritinib

                          Therapeutic Area : Immunology

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank